Bank of New York Mellon
LUMO

Bank of New York Mellon’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Bank of New York Mellon’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,858
Closed -$45.9K – 4186
2024
Q3 		$45.9K Hold
11,858
– – ﹤0.01% 4049
2024
Q2 		$27.5K Hold
11,858
– – ﹤0.01% 4075
2024
Q1 		$33.4K Hold
11,858
– – ﹤0.01% 4102
2023
Q4 		$37.7K Hold
11,858
– – ﹤0.01% 4182
2023
Q3 		$39.1K Hold
11,858
– – ﹤0.01% 4184
2023
Q2 		$39.1K Hold
11,858
– – ﹤0.01% 4213
2023
Q1 		$39.2K Hold
11,858
– – ﹤0.01% 4233
2022
Q4 		$42.8K Hold
11,858
– – ﹤0.01% 4262
2022
Q3 		$105K Hold
11,858
– – ﹤0.01% 4189
2022
Q2 		$91K Buy
11,858
+1
+0% +$8 ﹤0.01% 4243
2022
Q1 		$111K Hold
11,857
– – ﹤0.01% 4389
2021
Q4 		$83K Hold
11,857
– – ﹤0.01% 4432
2021
Q3 		$112K Sell
11,857
-4,104
-26% -$38.5K ﹤0.01% 4311
2021
Q2 		$159K Sell
15,961
-748
-4% -$8.33K ﹤0.01% 4140
2021
Q1 		$196K Sell
16,709
-784
-4% -$13.2K ﹤0.01% 4062
2020
Q4 		$625K Buy
+17,493
New +$302K ﹤0.01% 3502
2020
Q1 		– Sell
-7,949
Closed -$181K – 4201
2019
Q4 		$181K Hold
7,949
– – ﹤0.01% 3940
2019
Q3 		$114K Buy
7,949
+2,585
+48% +$37.9K ﹤0.01% 4005
2019
Q2 		$71K Sell
5,364
-10,658
-67% -$161K ﹤0.01% 4084
2019
Q1 		$278K Sell
16,022
-182
-1% -$2.71K ﹤0.01% 3768
2018
Q4 		$222K Buy
16,204
+2,788
+21% +$49.1K ﹤0.01% 3825
2018
Q3 		$289K Sell
13,416
-352
-3% -$10.7K ﹤0.01% 3837
2018
Q2 		$590K Sell
13,768
-64
-0.5% -$2.93K ﹤0.01% 3554
2018
Q1 		$903K Buy
13,832
+812
+6% +$57.5K ﹤0.01% 3277
2017
Q4 		$950K Buy
13,020
+1,467
+13% +$121K ﹤0.01% 3283
2017
Q3 		$1.06M Sell
11,553
-45
-0.4% -$3.45K ﹤0.01% 3187
2017
Q2 		$767K Sell
11,598
-10,906
-48% -$1.35M ﹤0.01% 3402
2017
Q1 		$4.88M Buy
22,504
+8,401
+60% +$1.2M ﹤0.01% 2333
2016
Q4 		$1.3M Sell
14,103
-2,214
-14% -$249K ﹤0.01% 3111
2016
Q3 		$2.21M Sell
16,317
-98
-0.6% -$9.73K ﹤0.01% 2702
2016
Q2 		$1.66M Buy
16,415
+322
+2% +$39.9K ﹤0.01% 2829
2016
Q1 		$2.64M Sell
16,093
-488
-3% -$98.9K ﹤0.01% 2503
2015
Q4 		$5.43M Buy
16,581
+4,337
+35% +$1.41M ﹤0.01% 2166
2015
Q3 		$3.95M Sell
12,244
-1,917
-14% -$842K ﹤0.01% 2361
2015
Q2 		$5.64M Buy
14,161
+898
+7% +$382K ﹤0.01% 2278
2015
Q1 		$6.53M Buy
13,263
+883
+7% +$342K ﹤0.01% 2169
2014
Q4 		$4.43M Buy
12,380
+158
+1% +$47K ﹤0.01% 2372
2014
Q3 		$2.36M Buy
12,222
+1,301
+12% +$286K ﹤0.01% 2758
2014
Q2 		$2.61M Sell
10,921
-793
-7% -$161K ﹤0.01% 2734
2014
Q1 		$2.99M Buy
11,714
+2,324
+25% +$710K ﹤0.01% 2610
2013
Q4 		$1.86M Buy
9,390
+647
+7% +$115K ﹤0.01% 2930
2013
Q3 		$1.48M Buy
8,743
+239
+3% +$38.5K ﹤0.01% 3028
2013
Q2 		$1.51M Buy
+8,504
New +$1.2M ﹤0.01% 2944

Bank of New York Mellon's LUMO Position: Q4 2024 in Review

Bank of New York Mellon sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 11,858 shares — an estimated $45.9K sold.

Bank of New York Mellon first reported a position in LUMO in Q2 2013 and held it in 43 quarters. The position peaked at $6.53M in Q1 2015. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.

  • Bank of New York Mellon reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 11,858 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $45.9K.
  • Bank of New York Mellon first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 43 quarters.
  • Bank of New York Mellon's Lumos Pharma, Inc. Common Stock position peaked at $6.53M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.

Based on Bank of New York Mellon's 13F filing for Q4 2024, filed 4 Feb 2025.